# J&J Says Second CAPLYTA Study Met Endpoints in Bipolar I Mania Trial

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/54028
Published: 2026-11-11T13:44:34.000Z
Updated: 2026-11-11T13:44:34.000Z
Section: Business

> Study 452 tested adults with bipolar I disorder experiencing manic episodes, with or without mixed features.

Johnson & Johnson (J&J) said Nov. 10 that its second pivotal Phase 3 study of CAPLYTA met its primary and key secondary endpoints in adults with bipolar I disorder experiencing manic episodes, with or without mixed features.

The study, identified as Study 452, marks a second late-stage success for CAPLYTA in bipolar mania.